TG Therapeutics
TGTX
240 hedge funds and large institutions have $4.76B invested in TG Therapeutics in 2021 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 89 increasing their positions, 76 reducing their positions, and 48 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 76
9% less call options, than puts
Call options by funds: $69.5M | Put options by funds: $76.3M
2.22% less ownership
Funds ownership: 72.51% → 70.29% (-2.2%)
3% less funds holding
Funds holding: 247 → 240 (-7)
8% less capital invested
Capital invested by funds: $5.19B → $4.76B (-$434M)
10% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 48
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$151M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$111M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$42.9M |
| 4 |
BlackRock
New York
|
+$35.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$195M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$44.2M |
| 3 |
LPC
Lion Point Capital
New York
|
-$34.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$32.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
276
Ameriprise
Minneapolis,
Minnesota
| – | -$206K | -3,951 | Closed |
|
|
QT
277
Quantbot Technologies
New York
| – | -$88K | -1,706 | Closed |
|
278
Walleye Trading
New York
| – | -$88K | -1,691 | Closed |
|
|
CAAS
279
Capital Asset Advisory Services
Williamston,
Michigan
| – | -$81K | -1,560 | Closed |
|
|
CG
280
Cutler Group
San Francisco,
California
| – | -$60K | -1,249 | Closed |
|
|
BBHC
281
Brown Brothers Harriman & Co
New York
| – | -$52K | -1,000 | Closed |
|
282
Simplex Trading
Chicago,
Illinois
| – | -$41.9K | -872 | -10% |
|
|
PWPS
283
Pinnacle Wealth Planning Services
Mansfield,
Ohio
| – | -$28K | -547 | Closed |
|
|
WAM
284
Wolverine Asset Management
Chicago,
Illinois
| – | -$24K | -471 | Closed |
|
|
ASN
285
Advisory Services Network
Atlanta,
Georgia
| – | -$21K | -400 | Closed |
|
|
ICP
286
Interchange Capital Partners
Pittsburgh,
Pennsylvania
| – | -$2K | -54 | Closed |
|
|
ABC
287
Associated Banc-Corp
Green Bay,
Wisconsin
| – | -$2K | -33 | Closed |
|
|
HWM
288
HighMark Wealth Management
St. Paul,
Minnesota
| – | +$48 | +1 | +6% |
|
TGTX Hedge Fund Activity: Q1 2021 in Review
240 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2021, worth a combined $4.76B — down 8.4% from $5.19B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TGTX and 43 opened new positions — a net loss of 5 holders — while 76 trimmed existing stakes and 89 added.
The largest buyer was Fidelity Investments, adding an estimated $151M. The largest seller was RA Capital Management, cutting an estimated $195M.
- 240 institutional investors held TG Therapeutics (TGTX) as of Q1 2021, down from 247 in Q4 2020.
- Funds reported $4.76B of TG Therapeutics stock for Q1 2021, down 8.4% quarter-over-quarter.
- 43 funds opened new TG Therapeutics positions in Q1 2021 and 48 closed out, a net change of -5 holders.
- The largest TG Therapeutics buyer in Q1 2021 was Fidelity Investments, an estimated $151M added.
- The largest TG Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $195M sold.
Based on aggregated 13F filings for Q1 2021.